'%20d='m0%200%2016%2011h61%2061%2061%2061%2060L47%2037h61%2061%2060%2061L16%2063h61%2061%2061%2061%2060L47%2089h61%2061%2060%2061L16%20115h61%2061%2061%2061%2060L47%20141h61%2061%2060%2061L16%20166h61%2061%2061%2061%2060L47%20192h61%2061%2060%2061L16%20218h61%2061%2061%2061%2060z'/%3e%3c/svg%3e){kind=small}
'%20transform='translate(89.8%20.4)scale(.9375)'%3e%3cpath%20fill='%23fff'%20d='M-95.8-.4H587v512H-95.8Z'/%3e%3cg%20transform='rotate(-56.3%20361.6%20-101.3)scale(10.66667)'%3e%3cg%20id='kr-c'%3e%3cpath%20id='kr-b'%20fill='%23000001'%20d='M-6-26H6v2H-6Zm0%203H6v2H-6Zm0%203H6v2H-6Z'/%3e%3cuse%20xlink:href='%23kr-b'%20width='100%25'%20height='100%25'%20y='44'/%3e%3c/g%3e%3cpath%20stroke='%23fff'%20d='M0%2017v10'/%3e%3cpath%20fill='%23cd2e3a'%20d='M0-12a12%2012%200%200%201%200%2024Z'/%3e%3cpath%20fill='%230047a0'%20d='M0-12a12%2012%200%200%200%200%2024A6%206%200%200%200%200%200Z'/%3e%3ccircle%20cy='-6'%20r='6'%20fill='%23cd2e3a'/%3e%3c/g%3e%3cg%20transform='rotate(-123.7%20191.2%2062.2)scale(10.66667)'%3e%3cuse%20xlink:href='%23kr-c'%20width='100%25'%20height='100%25'/%3e%3cpath%20stroke='%23fff'%20d='M0-23.5v3M0%2017v3.5m0%203v3'/%3e%3c/g%3e%3c/g%3e%3c/svg%3e){kind=small}
Dr. Karsten Miermans
Founder & CEO
Meet the team at hema.to
We are a deeptech AI company obsessed with improving cytometry and thereby have an outsized, lasting impact.
Felix Kunzweiler
Founder & CTO
Dr. Franz Elsner
Founder & Principal Scientist
Dr. Martin Becker
Head of Medical Affairs
Dr. Mohamad Kurdi
Flow Cytometry and Hematology Specialist
Daniel Moritz
CFO (interim)
Natalia Wlizlo
Quality Specialist
Younhee Park
Frontend Engineer
Magomed Abdulaev
Head of Ops
Clara Bodin
Back-office Manager
Dr. Florian Pfisterer
Senior Data and Applied Scientist
Felix Spöttel
Senior Software Engineer
Toni Urcola Peya
Senior Software Engineer
Dr. Aleks Mężydło
Chief Medical Officer
Ramy Moussa
Senior Software Engineer
hema.to by the numbers.
- Analyses supported by hema.to
- 4,000+
- FCS files in our database
- 600,000+
- Mean accuracy in our prospective interventional clinical study
- 98.6%
- Peer-reviewed publications
- 4